This fall marks half a year since COVID-19 was officially declared a pandemic, changing our lives forever. While this may seem a lifetime ago, the biopharma response is realistically only reaching the end of the beginning.

In this webinar, Pharma Intelligence reviews the progress made so far against the virus, operating within lockdown measures and the accompanying economic effects, while also laying out the path ahead. Considerable work remains in order to develop and commercialize effective therapeutics and vaccines at a global scale. In parallel, the industry must also recognize and not squander the opportunities that the pandemic has afforded in order to emerge from a post-COVID world in a position of strength.